Adipokines and the Risk of Reflux Esophagitis

Adipokines and the Risk of Reflux Esophagitis : Prospective Case-control Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01560598

Enrollment

600

Registered

2012-03-22

Start date

2012-06-30

Completion date

Unknown

Last updated

2012-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reflux Esophagitis, Visceral Obesity

Keywords

GERD, reflux esophagitis, adipokine, especially, endoscopically proven

Brief summary

We aimed to risk faoctors for GERD and association between visceral obesity, plasma adipoline(leptin, adiponectin, IL-6, TNF-α)and development of reflux esophagitis in healthy Koreans.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* endoscopically proven reflux esophagitis

Exclusion criteria

* those with esophageal hiatal hernia, current PPI medication, upper GI operation history

Design outcomes

Primary

Measure	Time frame
Difference in serum adipokine levels between case and control groups	2 month lager (after sampling)

Countries

South Korea

Contacts

Primary ContactKyung-Sang Yu, Professor

ksyu@snu.ac.kr+82-2-2072-1920

Backup ContactJeong-Hwa Hong, IRB analyst

jhhong@snu.ac.kr+82-2-740-8096

Outcome results